Syngene International Ltd

Summary

Syngene International Ltd.: Q2FY23 Result Update

About The Company

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.

Q2FY23 Operating Highlights

• Positive performance across all divisions
• Sustained growth in research divisions - Discovery Services, including Synvent, our integrated drug discovery platform - and the Dedicated Centres
• Growth in Development Services led by existing clients renewing contracts and setting up collaborations on additional projects
• Successfully completed the process performance qualification batches at a commercial scale for Zoetis
• On track for the regulatory audits, which will pave the way for the commercial manufacturing of the drug substance for Librela®*, a Zoetis product, from the fourth quarter of FY23
• Continued to invest in new infrastructure and capability-building

Key Facts and Figure

Business Segments

Research Business

Discovery Services

Flexible Platform with capability across multiple modalities including small molecule, large molecule,  peptides, oligonucleotides, antibody
drug conjugates, PROTACs

SynVent our proprietary platform for Integrated Drug Discovery

Dedicated R&D Centers

Ring-fenced infrastructure for exclusive operations for an individual client

Dedicated, multi-disciplinary team of scientists Access to entire Syngene ecosystem

for specialist research and development operations

Development and Manufacturing Business

Development Services

Pre-clinical to clinical trials

Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing Services

Manufacturing of small and large molecules for commercial supplies

cGMP-compliant facilities

State-of-the art API manufacturing and biologics manufacturing facilities

Capex Update

Financial Performance

Q2FY23 Financial Snapshot